×
Entrez Id: 6716
Gene Symbol: SRD5A2
SRD5A2
0.400
Biomarker
group
BEFREE
DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrence.
26332453 2015
×
Entrez Id: 6716
Gene Symbol: SRD5A2
SRD5A2
0.400
GeneticVariation
group
LHGDN
It is therefore possible that polymorphisms in the androgen synthesis gene 5alpha-reductase type II (SRD5A2 ) may be involved in the progression of prostate tumors .
19215786 2009
×
Entrez Id: 6716
Gene Symbol: SRD5A2
SRD5A2
0.400
Biomarker
group
BEFREE
It is therefore possible that polymorphisms in the androgen synthesis gene 5alpha-reductase type II (SRD5A2 ) may be involved in the progression of prostate tumors .
19215786 2009
×
Entrez Id: 6716
Gene Symbol: SRD5A2
SRD5A2
0.400
GeneticVariation
group
BEFREE
We sequenced 26 matched human prostate tumor and constitutional DNA samples for somatic alterations in the SRD5A2 , HPRT, and HSD3B2 genes, and identified 71 nucleotide substitutions.
18623241 2009
×
Entrez Id: 6716
Gene Symbol: SRD5A2
SRD5A2
0.400
GeneticVariation
group
LHGDN
No association between the SRD5A2 gene A49T missense variant and prostate cancer risk: lessons learned.
18469342 2008
×
Entrez Id: 6716
Gene Symbol: SRD5A2
SRD5A2
0.400
GeneticVariation
group
LHGDN
V89L polymorphism of the 5alpha-reductase Type II gene (SRD5A2), endogenous sex hormones, and prostate cancer risk.
18268111 2008
×
Entrez Id: 6716
Gene Symbol: SRD5A2
SRD5A2
0.400
Biomarker
group
CTD_human
The interaction of CYP3A5 polymorphisms along the androgen metabolism pathway in prostate cancer.
18306354 2008
×
Entrez Id: 6716
Gene Symbol: SRD5A2
SRD5A2
0.400
Biomarker
group
CTD_human
[Dutasteride in the treatment of hormone refractory prostate cancer].
18500220 2008
×
Entrez Id: 6716
Gene Symbol: SRD5A2
SRD5A2
0.400
Biomarker
group
LHGDN
The SRD5A2 V89L polymorphism is associated with severity of disease in men with early onset prostate cancer.
18780294 2008
×
Entrez Id: 6716
Gene Symbol: SRD5A2
SRD5A2
0.400
GeneticVariation
group
LHGDN
Polymorphisms in genes regulating androgen activity among prostate cancer low-risk Inuit men and high-risk Scandinavians.
17376218 2008
×
Entrez Id: 6716
Gene Symbol: SRD5A2
SRD5A2
0.400
GeneticVariation
group
LHGDN
5alpha-Reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia.
17136762 2007
×
Entrez Id: 6716
Gene Symbol: SRD5A2
SRD5A2
0.400
GeneticVariation
group
LHGDN
SRD5A2 and HSD3B2 polymorphisms are associated with prostate cancer risk and aggressiveness.
17823934 2007
×
Entrez Id: 6716
Gene Symbol: SRD5A2
SRD5A2
0.400
GeneticVariation
group
LHGDN
Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors.
17448593 2007
×
Entrez Id: 6716
Gene Symbol: SRD5A2
SRD5A2
0.400
Biomarker
group
CTD_human
SRD5A2 and HSD3B2 polymorphisms are associated with prostate cancer risk and aggressiveness.
17823934 2007
×
Entrez Id: 6716
Gene Symbol: SRD5A2
SRD5A2
0.400
Biomarker
group
CTD_human
5alpha-Reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia.
17136762 2007
×
Entrez Id: 6716
Gene Symbol: SRD5A2
SRD5A2
0.400
Biomarker
group
CTD_human
Systematic replication study of reported genetic associations in prostate cancer: Strong support for genetic variation in the androgen pathway.
16998812 2006
×
Entrez Id: 6716
Gene Symbol: SRD5A2
SRD5A2
0.400
Biomarker
group
LHGDN
Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer.
16018939 2005
×
Entrez Id: 6716
Gene Symbol: SRD5A2
SRD5A2
0.400
AlteredExpression
group
LHGDN
Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer.
15538746 2005
×
Entrez Id: 6716
Gene Symbol: SRD5A2
SRD5A2
0.400
GeneticVariation
group
LHGDN
The 5alpha-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population.
16039774 2005
×
Entrez Id: 6716
Gene Symbol: SRD5A2
SRD5A2
0.400
GeneticVariation
group
LHGDN
Serum sex steroid hormone levels and polymorphisms of CYP17 and SRD5A2: implication for prostate cancer risk.
15477877 2004
×
Entrez Id: 6716
Gene Symbol: SRD5A2
SRD5A2
0.400
GeneticVariation
group
LHGDN
Identification and characterization of somatic steroid 5alpha-reductase (SRD5A2) mutations in human prostate cancer tissue.
15326487 2004
×
Entrez Id: 6716
Gene Symbol: SRD5A2
SRD5A2
0.400
GeneticVariation
group
LHGDN
Polymorphic markers in the 5alpha-reductase type II gene and the incidence of prostate cancer.
12712437 2003
×
Entrez Id: 6716
Gene Symbol: SRD5A2
SRD5A2
0.400
GeneticVariation
group
LHGDN
Evaluation of SRD5A2 sequence variants in susceptibility to hereditary and sporadic prostate cancer.
12746845 2003
×
Entrez Id: 6716
Gene Symbol: SRD5A2
SRD5A2
0.400
AlteredExpression
group
LHGDN
The loss of 5alpha-reductase type I and type II mRNA expression in metastatic prostate cancer to bone and lymph node metastasis.
12738739 2003
×
Entrez Id: 6716
Gene Symbol: SRD5A2
SRD5A2
0.400
GeneticVariation
group
LHGDN
Association of V89L SRD5A2 polymorphism with prostate cancer development in a Japanese population.
12771801 2003